<!DOCTYPE html>
<html lang="it">
<head>
  <meta charset="UTF-8">
  <title>Switch TAO (Warfarin ‚Üî DOAC) ‚Äì Guida rapida per MMG</title>
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <style>
    :root {
      --bg: #0f172a;
      --bg-soft: #020617;
      --card: #0b1220;
      --accent: #22c55e;
      --accent-soft: rgba(34,197,94,0.1);
      --accent2: #38bdf8;
      --accent2-soft: rgba(56,189,248,0.1);
      --warning: #f97316;
      --warning-soft: rgba(249,115,22,0.12);
      --danger: #ef4444;
      --danger-soft: rgba(239,68,68,0.12);
      --text: #e5e7eb;
      --muted: #9ca3af;
      --border-soft: rgba(148,163,184,0.35);
      --shadow-soft: 0 18px 45px rgba(15,23,42,0.85);
      --radius-xl: 22px;
    }

    * {
      box-sizing: border-box;
    }

    body {
      margin: 0;
      font-family: system-ui, -apple-system, BlinkMacSystemFont, "Segoe UI", sans-serif;
      background: radial-gradient(circle at top left, #0f766e 0, #020617 45%, #020617 100%);
      color: var(--text);
      line-height: 1.5;
    }

    .page {
      max-width: 1200px;
      margin: 0 auto;
      padding: 32px 16px 48px;
    }

    header.hero {
      background: radial-gradient(circle at top left, rgba(56,189,248,0.14), rgba(15,23,42,0.96));
      border-radius: 32px;
      padding: 28px 24px;
      box-shadow: var(--shadow-soft);
      border: 1px solid rgba(148,163,184,0.4);
      display: grid;
      grid-template-columns: minmax(0, 2.2fr) minmax(0, 1.6fr);
      gap: 24px;
      position: relative;
      overflow: hidden;
    }

    header.hero::before {
      content: "";
      position: absolute;
      inset: -40%;
      background:
        radial-gradient(circle at 10% 0%, rgba(56,189,248,0.16), transparent 55%),
        radial-gradient(circle at 90% 0%, rgba(34,197,94,0.18), transparent 55%);
      opacity: 0.7;
      pointer-events: none;
      z-index: -1;
    }

    .hero-main h1 {
      margin: 0 0 12px;
      font-size: clamp(1.8rem, 3vw, 2.3rem);
      letter-spacing: 0.02em;
      display: flex;
      align-items: center;
      gap: 8px;
    }

    .hero-pill {
      display: inline-flex;
      align-items: center;
      gap: 6px;
      padding: 3px 10px;
      border-radius: 999px;
      border: 1px solid rgba(148,163,184,0.6);
      font-size: 0.78rem;
      color: var(--muted);
      margin-bottom: 10px;
      background: rgba(15,23,42,0.7);
    }

    .hero-main p {
      color: var(--muted);
      margin: 0 0 14px;
      font-size: 0.94rem;
    }

    .hero-tags {
      display: flex;
      flex-wrap: wrap;
      gap: 8px;
      margin-bottom: 12px;
    }

    .tag {
      font-size: 0.75rem;
      padding: 4px 9px;
      border-radius: 999px;
      background: rgba(15,23,42,0.85);
      border: 1px solid rgba(148,163,184,0.4);
      display: inline-flex;
      align-items: center;
      gap: 6px;
      color: var(--muted);
    }

    .hero-badges {
      display: grid;
      grid-template-columns: repeat(auto-fit, minmax(120px, 1fr));
      gap: 10px;
      margin-top: 6px;
    }

    .hero-badge {
      background: rgba(15,23,42,0.85);
      border-radius: 18px;
      padding: 10px 11px;
      border: 1px solid rgba(148,163,184,0.45);
      display: flex;
      flex-direction: column;
      gap: 2px;
      font-size: 0.8rem;
    }

    .hero-badge span {
      font-size: 0.7rem;
      color: var(--muted);
    }

    .hero-badge strong {
      font-size: 0.9rem;
    }

    .hero-right {
      position: relative;
      display: flex;
      align-items: center;
      justify-content: center;
    }

    .dial-card {
      width: 100%;
      max-width: 260px;
      background: linear-gradient(145deg, rgba(15,23,42,0.96), rgba(15,23,42,0.86));
      border-radius: 28px;
      padding: 16px 16px 18px;
      border: 1px solid rgba(148,163,184,0.55);
      box-shadow: 0 18px 45px rgba(0,0,0,0.85);
    }

    .dial-header {
      display: flex;
      justify-content: space-between;
      align-items: center;
      font-size: 0.76rem;
      color: var(--muted);
      margin-bottom: 6px;
    }

    .pill-small {
      padding: 2px 7px;
      border-radius: 999px;
      background: rgba(15,23,42,0.85);
      border: 1px solid rgba(148,163,184,0.5);
      font-size: 0.7rem;
      display: inline-flex;
      align-items: center;
      gap: 4px;
    }

    .dial-svg {
      width: 100%;
      margin: 6px 0;
    }

    .dial-legend {
      display: flex;
      justify-content: space-between;
      font-size: 0.7rem;
      color: var(--muted);
      margin-top: 4px;
    }

    .badge-status {
      margin-top: 8px;
      font-size: 0.78rem;
      padding: 6px 8px;
      border-radius: 999px;
      display: inline-flex;
      align-items: center;
      gap: 6px;
      background: rgba(34,197,94,0.12);
      border: 1px solid rgba(34,197,94,0.7);
      color: #bbf7d0;
    }

    main {
      margin-top: 28px;
      display: grid;
      grid-template-columns: minmax(0, 1.9fr) minmax(0, 1.2fr);
      gap: 22px;
    }

    @media (max-width: 900px) {
      header.hero {
        grid-template-columns: minmax(0, 1fr);
      }
      main {
        grid-template-columns: minmax(0, 1fr);
      }
    }

    @media (max-width: 640px) {
      .page {
        padding-inline: 12px;
      }
      header.hero {
        padding: 20px 16px;
      }
    }

    .section {
      background: rgba(15,23,42,0.96);
      border-radius: var(--radius-xl);
      padding: 18px 18px 20px;
      border: 1px solid var(--border-soft);
      box-shadow: 0 16px 40px rgba(15,23,42,0.9);
      margin-bottom: 20px;
      position: relative;
      overflow: hidden;
    }

    .section::before {
      content: "";
      position: absolute;
      inset: 0;
      background: radial-gradient(circle at top left, rgba(56,189,248,0.13), transparent 55%);
      opacity: 0.45;
      pointer-events: none;
      mix-blend-mode: screen;
    }

    .section > * {
      position: relative;
      z-index: 1;
    }

    .section h2 {
      margin: 0 0 6px;
      font-size: 1.08rem;
      letter-spacing: 0.03em;
      display: flex;
      align-items: center;
      gap: 8px;
    }

    .section h3 {
      margin: 14px 0 4px;
      font-size: 0.96rem;
      display: flex;
      align-items: center;
      gap: 6px;
    }

    .section p {
      font-size: 0.86rem;
      color: var(--muted);
      margin: 4px 0;
    }

    .pill-label {
      display: inline-flex;
      align-items: center;
      gap: 6px;
      padding: 2px 8px;
      border-radius: 999px;
      background: rgba(15,23,42,0.9);
      border: 1px solid rgba(148,163,184,0.45);
      font-size: 0.72rem;
      color: var(--muted);
      margin-bottom: 6px;
    }

    ul.clean {
      list-style: none;
      padding-left: 0;
      margin: 6px 0 0;
    }

    ul.clean li {
      font-size: 0.85rem;
      color: var(--muted);
      padding: 4px 0;
      display: flex;
      gap: 6px;
      align-items: flex-start;
    }

    ul.clean li span.bullet {
      font-size: 0.9rem;
      margin-top: 0;
      min-width: 16px;
    }

    .grid-2 {
      display: grid;
      grid-template-columns: repeat(2, minmax(0,1fr));
      gap: 10px;
    }

    @media (max-width: 720px) {
      .grid-2 {
        grid-template-columns: minmax(0,1fr);
      }
    }

    .card-soft {
      background: rgba(15,23,42,0.9);
      border-radius: 18px;
      padding: 10px 11px;
      border: 1px solid rgba(148,163,184,0.5);
      font-size: 0.82rem;
    }

    .card-soft h4 {
      margin: 0 0 4px;
      font-size: 0.9rem;
      display: flex;
      gap: 6px;
      align-items: center;
    }

    .badge {
      display: inline-flex;
      padding: 2px 7px;
      border-radius: 999px;
      font-size: 0.7rem;
      background: rgba(15,23,42,0.9);
      border: 1px solid rgba(148,163,184,0.6);
      color: var(--muted);
      gap: 6px;
      align-items: center;
    }

    .badge.badge-green {
      background: var(--accent-soft);
      border-color: rgba(34,197,94,0.8);
      color: #bbf7d0;
    }

    .badge.badge-orange {
      background: var(--warning-soft);
      border-color: rgba(249,115,22,0.85);
      color: #fed7aa;
    }

    .badge.badge-red {
      background: var(--danger-soft);
      border-color: rgba(239,68,68,0.9);
      color: #fecaca;
    }

    .table-wrapper {
      margin-top: 8px;
      border-radius: 14px;
      overflow: hidden;
      border: 1px solid rgba(148,163,184,0.6);
    }

    table {
      border-collapse: collapse;
      width: 100%;
      font-size: 0.8rem;
      background: rgba(15,23,42,0.96);
    }

    thead {
      background: linear-gradient(90deg, #0ea5e9, #22c55e);
    }

    thead th {
      padding: 6px 8px;
      text-align: left;
      color: #e5f3ff;
      font-weight: 600;
      border-bottom: 1px solid rgba(15,23,42,0.4);
    }

    tbody td {
      padding: 6px 8px;
      border-top: 1px solid rgba(51,65,85,0.7);
      color: var(--muted);
    }

    tbody tr:nth-child(even) {
      background: rgba(15,23,42,0.92);
    }

    tbody tr:nth-child(odd) {
      background: rgba(15,23,42,0.86);
    }

    .timeline {
      margin-top: 10px;
      position: relative;
      padding-left: 18px;
    }

    .timeline::before {
      content: "";
      position: absolute;
      left: 7px;
      top: 0;
      bottom: 0;
      width: 2px;
      background: linear-gradient(to bottom, rgba(56,189,248,0.2), rgba(34,197,94,0.7));
    }

    .timeline-item {
      position: relative;
      margin-bottom: 10px;
      padding-left: 12px;
    }

    .timeline-dot {
      position: absolute;
      left: -3px;
      top: 4px;
      width: 12px;
      height: 12px;
      border-radius: 999px;
      background: #0f172a;
      border: 3px solid var(--accent2);
      box-shadow: 0 0 0 4px rgba(56,189,248,0.15);
    }

    .timeline-item h4 {
      margin: 0 0 2px;
      font-size: 0.86rem;
    }

    .timeline-item p {
      margin: 0;
      font-size: 0.8rem;
      color: var(--muted);
    }

    .alert {
      margin-top: 8px;
      border-radius: 16px;
      padding: 8px 10px;
      font-size: 0.8rem;
      display: flex;
      gap: 8px;
      align-items: flex-start;
    }

    .alert.alert-warning {
      background: var(--warning-soft);
      border: 1px solid rgba(249,115,22,0.9);
      color: #fed7aa;
    }

    .alert.alert-danger {
      background: var(--danger-soft);
      border: 1px solid rgba(239,68,68,0.9);
      color: #fecaca;
    }

    .alert strong {
      display: block;
      margin-bottom: 2px;
    }

    .checklist {
      display: grid;
      grid-template-columns: repeat(2, minmax(0, 1fr));
      gap: 6px;
      margin-top: 6px;
    }

    @media (max-width: 640px) {
      .checklist {
        grid-template-columns: minmax(0,1fr);
      }
    }

    .check-item {
      display: flex;
      align-items: flex-start;
      gap: 6px;
      font-size: 0.83rem;
      color: var(--muted);
    }

    .check-box {
      width: 18px;
      height: 18px;
      border-radius: 6px;
      border: 1px solid rgba(148,163,184,0.7);
      display: inline-flex;
      align-items: center;
      justify-content: center;
      font-size: 0.8rem;
      color: var(--accent2);
      margin-top: 1px;
    }

    footer {
      margin-top: 10px;
      font-size: 0.76rem;
      color: var(--muted);
      text-align: right;
      opacity: 0.75;
    }
  </style>
</head>
<body>
  <div class="page">

    <!-- HERO -->
    <header class="hero">
      <div class="hero-main">
        <div class="hero-pill">
          üß≠ Guida pratica allo <strong>switch Warfarin ‚Üî DOAC</strong> per MMG
        </div>
        <h1>ü©∫ TAO ‚Äì Switch sicuro tra AVK e DOAC</h1>
        <p>
          Schema operativo per gestire i passaggi Warfarin/Acenocumarolo ‚Üî DOAC
          minimizzando il rischio di <strong>finestra scoperta</strong> (ictus) e
          <strong>sovrapposizione eccessiva</strong> (emorragia maggiore).
        </p>

        <div class="hero-tags">
          <div class="tag">üìå FANV ‚Äì pratica ambulatoriale MMG</div>
          <div class="tag">üß™ INR‚Äìcentrico per switch da/verso Warfarin</div>
          <div class="tag">üßÆ Cockcroft‚ÄìGault per la funzione renale</div>
        </div>

        <div class="hero-badges">
          <div class="hero-badge">
            <span>Da AVK ‚ûú DOAC</span>
            <strong>Regola chiave: <br>iniziare DOAC solo a INR sotto soglia.</strong>
          </div>
          <div class="hero-badge">
            <span>Da DOAC ‚ûú AVK</span>
            <strong>Overlap / EBPM per coprire l‚Äôemivita breve.</strong>
          </div>
          <div class="hero-badge">
            <span>Popolazioni speciali</span>
            <strong>CKD, anziani fragili, obesit√†, APS, valvole.</strong>
          </div>
        </div>
      </div>

      <div class="hero-right">
        <div class="dial-card">
          <div class="dial-header">
            <span>Visualizzatore INR per switch</span>
            <span class="pill-small">Range TAO <strong>2‚Äì3</strong></span>
          </div>
          <!-- Simple semicircle dial SVG -->
          <svg class="dial-svg" viewBox="0 0 220 110">
            <!-- semicircle background -->
            <defs>
              <linearGradient id="gradRisk" x1="0%" y1="0%" x2="100%" y2="0%">
                <stop offset="0%" stop-color="#22c55e" />
                <stop offset="50%" stop-color="#eab308" />
                <stop offset="100%" stop-color="#ef4444" />
              </linearGradient>
            </defs>
            <path d="M15 100 A95 95 0 0 1 205 100" fill="none" stroke="url(#gradRisk)" stroke-width="14" />
            <!-- ticks -->
            <g stroke="#1f2937" stroke-width="2">
              <line x1="60" y1="92" x2="60" y2="78" />
              <line x1="110" y1="92" x2="110" y2="72" />
              <line x1="160" y1="92" x2="160" y2="78" />
            </g>
            <!-- labels -->
            <text x="60" y="72" fill="#9ca3af" font-size="10" text-anchor="middle">1.5</text>
            <text x="110" y="62" fill="#e5e7eb" font-size="11" text-anchor="middle">2.0‚Äì3.0</text>
            <text x="160" y="72" fill="#fca5a5" font-size="10" text-anchor="middle">>3.5</text>
            <!-- indicator dot (example near INR 2.2) -->
            <circle cx="118" cy="80" r="6" fill="#e5e7eb" />
          </svg>
          <div class="dial-legend">
            <span>üü¢ Sotto‚Äìanticoagulato</span>
            <span>üü° Range terapeutico</span>
            <span>üî¥ Sovradosaggio</span>
          </div>
          <div class="badge-status">
            ‚úÖ Focus switch: <strong>entra col DOAC quando il Warfarin ‚Äúmolla‚Äù</strong>
          </div>
        </div>
      </div>
    </header>

    <main>
      <!-- COLONNA SINISTRA -->
      <div>

        <!-- SEZIONE 1: PRINCIPI -->
        <section class="section">
          <h2>üéØ 1. Principi generali per lo switch TAO</h2>
          <p>
            Prima di modificare terapia, verificare che il paziente sia un candidato idoneo al nuovo
            farmaco (FANV non valvolare, assenza di protesi meccaniche, APS ad alto rischio, gravidanza, ecc.).
          </p>
          <div class="grid-2" style="margin-top:8px;">
            <div class="card-soft">
              <h4>üß¨ AVK (Warfarin / Acenocumarolo)</h4>
              <p>
                ‚Ä¢ Lunga emivita, ampia ‚Äúcoda‚Äù farmacologica<br>
                ‚Ä¢ Monitoraggio necessario tramite <strong>INR</strong><br>
                ‚Ä¢ Effetto protettivo residuo nello switch ‚ûú DOAC
              </p>
            </div>
            <div class="card-soft">
              <h4>üíä DOAC (Dabigatran / Apixaban / Rivaroxaban / Edoxaban)</h4>
              <p>
                ‚Ä¢ Onset rapido (picco 1‚Äì4h), emivita breve<br>
                ‚Ä¢ Nessun monitoraggio di routine (no INR)<br>
                ‚Ä¢ Salti o sospensioni = rischio di ‚Äúfinestra scoperta‚Äù
              </p>
            </div>
          </div>

          <div class="alert alert-danger">
            <div>‚ö†Ô∏è</div>
            <div>
              <strong>Punti critici della transizione</strong>
              <ul class="clean">
                <li><span class="bullet">‚è±Ô∏è</span><span><b>Timing errato</b> ‚ûú scopertura trombotica (ictus/TEV).</span></li>
                <li><span class="bullet">üíâ</span><span><b>Sovrapposizione eccessiva</b> ‚ûú sanguinamento maggiore.</span></li>
                <li><span class="bullet">üìè</span><span><b>INR falsato</b> dalla presenza di DOAC se misurato fuori ‚Äúvalle‚Äù.</span></li>
              </ul>
            </div>
          </div>
        </section>

        <!-- SEZIONE 2: VKA -> DOAC -->
        <section class="section">
          <h2>üîÑ 2. Switch da Warfarin / Acenocumarolo ‚ûú DOAC</h2>
          <div class="pill-label">Regola generale: <strong>‚Äústop &amp; wait‚Äù</strong> con monitoraggio INR</div>
          <p>
            Sospendere AVK e controllare l‚ÄôINR: il DOAC si avvia solo quando l‚ÄôINR √® sceso sotto la soglia
            specifica per evitare somma di anticoagulazione.
          </p>

          <div class="table-wrapper">
            <table>
              <thead>
                <tr>
                  <th>DOAC</th>
                  <th>Soglia INR per inizio</th>
                  <th>Note operative</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td><strong>Apixaban</strong></td>
                  <td><strong>&lt; 2.0</strong></td>
                  <td>FA: 5 mg BID (2,5 mg BID se ‚â•80 anni + peso ‚â§60 kg + creatinina ‚â•1,5 mg/dL).</td>
                </tr>
                <tr>
                  <td><strong>Dabigatran</strong></td>
                  <td><strong>&lt; 2.0</strong></td>
                  <td>150 mg BID (110 mg BID ‚â•80 anni o alto rischio sanguinamento). <b>Controindicato se ClCr &lt;30</b>.</td>
                </tr>
                <tr>
                  <td><strong>Edoxaban</strong></td>
                  <td><strong>‚â§ 2.5</strong></td>
                  <td>60 mg OD; ridurre a 30 mg OD se peso ‚â§60 kg, ClCr 30‚Äì50 o inibitori P-gp.</td>
                </tr>
                <tr>
                  <td><strong>Rivaroxaban</strong></td>
                  <td><strong>‚â§ 2.5‚Äì3.0</strong></td>
                  <td>FA: 20 mg OD con il pasto principale (15 mg se ClCr 15‚Äì49 ml/min).</td>
                </tr>
              </tbody>
            </table>
          </div>

          <div class="grid-2" style="margin-top:10px;">
            <div class="card-soft">
              <h4>‚è≥ Aspettarsi la discesa dell‚ÄôINR</h4>
              <ul class="clean">
                <li><span class="bullet">üíä</span><span><b>Warfarin</b>: l‚ÄôINR cala di ~0,5‚Äì1 punto in 2‚Äì3 giorni (variabile).</span></li>
                <li><span class="bullet">üíä</span><span><b>Acenocumarolo</b>: discesa pi√π rapida; spesso DOAC avviabile entro 24‚Äì48h.</span></li>
              </ul>
            </div>
            <div class="card-soft">
              <h4>üö´ Cosa evitare</h4>
              <ul class="clean">
                <li><span class="bullet">‚ùå</span><span>Non utilizzare <b>dosi di carico</b> dei DOAC (protocolli TVP/EP) per lo switch FA.</span></li>
                <li><span class="bullet">‚ùå</span><span>Non iniziare il DOAC con INR ancora nettamente sopra soglia.</span></li>
              </ul>
            </div>
          </div>
        </section>

        <!-- SEZIONE 3: DOAC -> VKA -->
        <section class="section">
          <h2>üîÅ 3. Switch da DOAC ‚ûú Warfarin</h2>
          <p>
            Transizione pi√π delicata: si passa da farmaco a <strong>emivita breve</strong> a farmaco a
            <strong>latenza lunga</strong>. Serve copertura con overlap DOAC‚Äìwarfarin o bridging con EBPM.
          </p>

          <div class="alert alert-warning">
            <div>üß™</div>
            <div>
              <strong>INR e DOAC</strong>
              <p>
                I DOAC (anti-Xa e dabigatran) possono <b>falsare verso l‚Äôalto l‚ÄôINR</b>. Misurare sempre l‚ÄôINR
                <b>al valle</b>, cio√® immediatamente prima della dose successiva di DOAC durante la
                sovrapposizione.
              </p>
            </div>
          </div>

          <h3>üíâ 3.1 Dabigatran ‚ûú Warfarin (overlap modulato su ClCr)</h3>
          <div class="timeline">
            <div class="timeline-item">
              <div class="timeline-dot"></div>
              <h4>ClCr ‚â• 50 ml/min ‚Äì overlap 3 giorni</h4>
              <p>Iniziare warfarin mentre si prosegue dabigatran per 3 giorni, poi sospendere dabigatran.</p>
            </div>
            <div class="timeline-item">
              <div class="timeline-dot"></div>
              <h4>ClCr 30‚Äì49 ml/min ‚Äì overlap 2 giorni</h4>
              <p>Funzione renale ridotta ‚ûú dabigatran si elimina pi√π lentamente: overlap pi√π breve.</p>
            </div>
            <div class="timeline-item">
              <div class="timeline-dot"></div>
              <h4>ClCr 15‚Äì29 ml/min ‚Äì overlap 1 giorno</h4>
              <p>Alto rischio di accumulo ‚ûú sovrapposizione minima.</p>
            </div>
          </div>
          <p style="margin-top:6px;">
            Misurare INR pre-dose durante overlap; dopo sospensione di dabigatran continuare warfarin
            con controlli ravvicinati finch√© INR stabile 2‚Äì3.
          </p>

          <h3>üåì 3.2 Edoxaban ‚ûú Warfarin (‚Äúhalf-dose protocol‚Äù)</h3>
          <div class="grid-2">
            <div class="card-soft">
              <h4>Schema pratico</h4>
              <ul class="clean">
                <li><span class="bullet">1Ô∏è‚É£</span><span>Ridurre <b>edoxaban alla met√†</b> (60‚Üí30 mg; 30‚Üí15 mg).</span></li>
                <li><span class="bullet">2Ô∏è‚É£</span><span>Iniziare warfarin in contemporanea.</span></li>
                <li><span class="bullet">3Ô∏è‚É£</span><span>Controllare INR (sempre pre-dose) ogni 2‚Äì3 giorni.</span></li>
                <li><span class="bullet">4Ô∏è‚É£</span><span>Sospendere edoxaban quando INR ‚â•2,0 ‚ûú proseguire solo warfarin.</span></li>
              </ul>
            </div>
            <div class="card-soft">
              <h4>üí° Perch√© met√† dose?</h4>
              <p>
                Edoxaban a dose ridotta mantiene copertura evitando eccessiva interferenza sull‚ÄôINR e limita il rischio
                emorragico durante la salita dell‚Äôeffetto di warfarin.
              </p>
            </div>
          </div>

          <h3>ü©∏ 3.3 Apixaban / Rivaroxaban ‚ûú Warfarin (bridging con EBPM)</h3>
          <p>
            Per gli inibitori del Xa le linee guida suggeriscono, nella pratica MMG, l‚Äôuso di EBPM a dose terapeutica
            durante la fase di passaggio.
          </p>
          <div class="timeline">
            <div class="timeline-item">
              <div class="timeline-dot"></div>
              <h4>Step 1 ‚Äì Stop DOAC</h4>
              <p>Sospendere apixaban o rivaroxaban alla data prevista.</p>
            </div>
            <div class="timeline-item">
              <div class="timeline-dot"></div>
              <h4>Step 2 ‚Äì EBPM + Warfarin</h4>
              <p>
                Al momento della dose successiva di DOAC: iniziare <b>EBPM terapeutica</b> (es. enoxaparina 1 mg/kg x2/die)
                + <b>warfarin</b> (dose d‚Äôattacco adattata all‚Äôet√†).
              </p>
            </div>
            <div class="timeline-item">
              <div class="timeline-dot"></div>
              <h4>Step 3 ‚Äì Monitoraggio INR</h4>
              <p>Controllo INR quotidiano o ogni 2 giorni.</p>
            </div>
            <div class="timeline-item">
              <div class="timeline-dot"></div>
              <h4>Step 4 ‚Äì Stop EBPM</h4>
              <p>Sospendere EBPM quando INR ‚â•2 per almeno 2 determinazioni consecutive (e ‚â•5 giorni di warfarin totali).</p>
            </div>
          </div>

          <div class="alert alert-warning">
            <div>üí°</div>
            <div>
              <strong>Alternativa (solo dove davvero necessario)</strong>
              <p>
                In pazienti selezionati si pu√≤ valutare co-somministrazione DOAC‚Äìwarfarin senza EBPM, con INR misurato
                a valle DOAC; alto rischio di interpretazione errata dell‚ÄôINR ‚ûú da riservare a setting controllati.
              </p>
            </div>
          </div>
        </section>

      </div>

      <!-- COLONNA DESTRA -->
      <div>

        <!-- SEZIONE 4: POPOLAZIONI SPECIALI -->
        <section class="section">
          <h2>üë• 4. Popolazioni particolari</h2>

          <div class="card-soft">
            <h4>üö∞ 4.1 Insufficienza renale (ClCr ‚Äì Cockcroft‚ÄìGault)</h4>
            <p>La funzione renale condiziona <b>scelta del DOAC</b> e <b>schema di switch</b>.</p>
            <div class="table-wrapper">
              <table>
                <thead>
                  <tr>
                    <th>DOAC</th>
                    <th>ClCr 30‚Äì50</th>
                    <th>ClCr 15‚Äì29</th>
                    <th>&lt;15 ml/min / dialisi</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td>Dabigatran</td>
                    <td>110 mg BID; usare cautela.</td>
                    <td>‚ùå Controindicato.</td>
                    <td>‚ùå Non usare.</td>
                  </tr>
                  <tr>
                    <td>Rivaroxaban</td>
                    <td>15 mg OD (FA).</td>
                    <td>Usare con estrema prudenza.</td>
                    <td>Non raccomandato.</td>
                  </tr>
                  <tr>
                    <td>Apixaban</td>
                    <td>5 mg BID (o 2,5 mg BID se criteri riduzione).</td>
                    <td>Spesso 2,5 mg BID (con cautela).</td>
                    <td>Off-label in dialisi; in genere meglio AVK.</td>
                  </tr>
                  <tr>
                    <td>Edoxaban</td>
                    <td>30 mg OD.</td>
                    <td>30 mg OD.</td>
                    <td>Non raccomandato.</td>
                  </tr>
                </tbody>
              </table>
            </div>
          </div>

          <div class="grid-2" style="margin-top:10px;">
            <div class="card-soft">
              <h4>üë¥ 4.2 Grandi anziani e fragili</h4>
              <ul class="clean">
                <li><span class="bullet">‚úÖ</span><span><b>Apixaban / Edoxaban</b> in genere meglio tollerati (meno sanguinamenti maggiori).</span></li>
                <li><span class="bullet">üíä</span><span><b>Dabigatran</b> 110 mg BID ‚â•80 anni, se scelto.</span></li>
                <li><span class="bullet">üß†</span><span>Valutare cadute, aderenza, supporto familiare.</span></li>
              </ul>
            </div>
            <div class="card-soft">
              <h4>‚öñÔ∏è 4.3 Obesit√† e peso estremo</h4>
              <ul class="clean">
                <li><span class="bullet">‚ö†Ô∏è</span><span>Dati limitati se peso &gt;120‚Äì150 kg (BMI &gt;40).</span></li>
                <li><span class="bullet">üìè</span><span>In questi casi si pu√≤ preferire <b>warfarin</b> (monitorabile con INR).</span></li>
                <li><span class="bullet">üß™</span><span>Eventuale dosaggio anti-Xa se persiste dubbio su livelli DOAC.</span></li>
              </ul>
            </div>
          </div>

          <div class="card-soft" style="margin-top:10px;">
            <h4>‚ù§Ô∏è 4.4 Valvulopatie &amp; APS</h4>
            <ul class="clean">
              <li><span class="bullet">üö´</span><span><b>Protesi meccaniche</b> e stenosi mitralica reumatica moderato‚Äìsevera: DOAC controindicati ‚ûú mantenere o tornare a <b>warfarin</b>.</span></li>
              <li><span class="bullet">üß¨</span><span><b>APS ad alto rischio (tripla positivit√†)</b>: preferibile warfarin; se su DOAC, considerare switch a AVK con bridging adeguato.</span></li>
            </ul>
          </div>

        </section>

        <!-- SEZIONE 5: INTERAZIONI -->
        <section class="section">
          <h2>üß© 5. Interazioni e farmaci ‚Äúnemici‚Äù dei DOAC</h2>
          <p>
            Valutare sempre interazioni P-gp / CYP3A4 prima dello switch: possono mandare fuori
            range i livelli dei DOAC.
          </p>
          <div class="grid-2">
            <div class="card-soft">
              <h4>‚¨áÔ∏è Induttori forti (rischio trombosi)</h4>
              <ul class="clean">
                <li><span class="bullet">üíä</span><span>Carbamazepina, fenitoina, fenobarbital.</span></li>
                <li><span class="bullet">üíä</span><span>Rifampicina.</span></li>
                <li><span class="bullet">üìå</span><span>In genere: <b>evitare DOAC</b>, preferire warfarin.</span></li>
              </ul>
            </div>
            <div class="card-soft">
              <h4>‚¨ÜÔ∏è Inibitori forti (rischio sanguinamento)</h4>
              <ul class="clean">
                <li><span class="bullet">üíä</span><span>Ketoconazolo, itraconazolo, alcuni antivirali (es. ritonavir).</span></li>
                <li><span class="bullet">üíä</span><span>Dronedarone, verapamil: ridurre dose di alcuni DOAC (es. edoxaban).</span></li>
              </ul>
            </div>
          </div>

          <div class="alert alert-danger">
            <div>‚ùó</div>
            <div>
              <strong>Errore frequente</strong>
              <p>
                Valutare solo le interazioni del warfarin e ‚Äúdimenticare‚Äù quelle del DOAC in arrivo.
                Prima dello switch, rivedere sempre terapia cronica (antiepilettici, anti‚ÄìHIV, antimicotici,
                antiaritmici) e scegliere l‚Äôanticoagulante pi√π compatibile.
              </p>
            </div>
          </div>
        </section>

        <!-- SEZIONE 6: CHECKLIST -->
        <section class="section">
          <h2>üìù 6. Checklist rapida per MMG</h2>
          <p>Da usare ogni volta che si valuta uno switch TAO in ambulatorio.</p>
          <div class="checklist">
            <div class="check-item">
              <div class="check-box">‚úî</div>
              <div>Definita la <b>direzione dello switch</b> (AVK ‚ûú DOAC o DOAC ‚ûú AVK).</div>
            </div>
            <div class="check-item">
              <div class="check-box">‚úî</div>
              <div>Calcolata la <b>ClCr (Cockcroft‚ÄìGault)</b> e scelta molecola/dose di conseguenza.</div>
            </div>
            <div class="check-item">
              <div class="check-box">‚úî</div>
              <div>Escluse <b>controindicazioni a DOAC</b> (valvole meccaniche, APS ad alto rischio, gravidanza).</div>
            </div>
            <div class="check-item">
              <div class="check-box">‚úî</div>
              <div>Riviste <b>interazioni farmacologiche</b> (induttori/inibitori P-gp/CYP3A4).</div>
            </div>
            <div class="check-item">
              <div class="check-box">‚úî</div>
              <div>Stabilita la <b>soglia INR</b> per avviare il DOAC o per sospendere il DOAC (in switch verso warfarin).</div>
            </div>
            <div class="check-item">
              <div class="check-box">‚úî</div>
              <div>Decisa la necessit√† di <b>overlap o bridging</b> (dabigatran/edoxaban vs apixaban/rivaroxaban).</div>
            </div>
            <div class="check-item">
              <div class="check-box">‚úî</div>
              <div>Pianificato il <b>follow-up</b>: creatinina + emocromo a 1 mese, poi ogni 3‚Äì6 mesi.</div>
            </div>
            <div class="check-item">
              <div class="check-box">‚úî</div>
              <div>Informato il paziente su <b>aderenza</b>, cosa fare in caso di dimenticanza dose, segni di allarme.</div>
            </div>
          </div>
        </section>

        <footer>
          Materiale di supporto per MMG ‚Äì adattabile come scheda digitale, stampa A4 o contenuto web.
        </footer>

      </div>
    </main>
  </div>
</body>
</html>
